Lipid-lowering therapy: strategies for improving compliance
- 1 January 2004
- journal article
- review article
- Published by Taylor & Francis in Current Medical Research and Opinion
- Vol. 20 (2) , 165-173
- https://doi.org/10.1185/030079903125002810
Abstract
SUMMARYLowering cholesterol levels is a primary approach for reducing the risk of coronary heart disease (CHD), yet patients rarely achieve the lipid targets recommended by international guidelines. Although high rates of compliance and achievement of lipid targets have been reported in clinical trials, this situation is infrequently reproduced in regular practice. This sub-optimal lipid management has clinical consequences as patients will not gain the full benefit of treatment. Poor compliance with therapeutic lifestyle changes and/or lipid-lowering agents is thought to contribute to the failure of patients in clinical practice to achieve lipid targets, and therefore this problem needs to be addressed. Several approaches may be used to improve compliance, including the prescription of efficacious, well-tolerated agents, educating patients about the necessity of therapy, and regular follow-up to monitor compliance and achievement of goals. However, educating patients to promote compliant behaviour can be...Keywords
This publication has 60 references indexed in Scilit:
- Treating dyslipidemia with statins: The risk-benefit profileAmerican Heart Journal, 2003
- Pharmacokinetic-Pharmacodynamic Drug Interactions with HMG-CoA Reductase InhibitorsClinical Pharmacokinetics, 2002
- Does a Lipid Clinic Increase Compliance With National Cholesterol Education Program Treatment Guidelines?Southern Medical Journal, 2001
- Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)JAMA, 2001
- Enhancing Drug Compliance in Lipid-Lowering TreatmentArchives of Family Medicine, 2000
- From best evidence to best practice — what are the obstacles?Atherosclerosis, 1999
- Prevention of Cardiovascular Events and Death with Pravastatin in Patients with Coronary Heart Disease and a Broad Range of Initial Cholesterol LevelsNew England Journal of Medicine, 1998
- Comparative Dose Efficacy Study of Atorvastatin Versus Simvastatin, Pravastatin, Lovastatin, and Fluvastatin in Patients With Hypercholesterolemia (The CURVES Study) fn1fn1This study was supported by Parke-Davis, Division of Warner Lambert Company, Morris Plains, New Jersey. Manuscript received August 20, 1997; revised manuscript received and accepted November 24, 1997.The American Journal of Cardiology, 1998
- The role of medication noncompliance and adverse drug reactions in hospitalizations of the elderlyArchives of internal medicine (1960), 1990
- Strategies for enhancing patient complianceJournal of Community Health, 1980